Person · CIK 1560782

James M Daly

Director at Cytokinetics, Halozyme Therapeutics, Madrigal Pharmaceuticals and Acadia Pharmaceuticals

Earlier: Bellicum Pharmaceuticals, Chimerix and Incyte

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$44.4M

Noticed on Form 144$15.6M

Bought on Form 4$0

Companies7

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Cytokinetics CYTK	Common Stock	Directly	3,585	Oct 16, 2026 · Filing · EDGAR
Cytokinetics CYTK	Non-Qualified Stock Option (Right to Buy) exercise $77.15, expires May 26, 2036, into Common Stock	Directly	4,301	May 27, 2026 · Filing · EDGAR
Halozyme Therapeutics HALO	Restricted Stock Unit	Directly	32,438	May 5, 2022 · Filing · EDGAR
Halozyme Therapeutics HALO	Common Stock	Directly	20,503	Aug 14, 2023 · Filing · EDGAR
Halozyme Therapeutics HALO	Restricted Stock Units	Directly	1,169	Oct 1, 2026 · Filing · EDGAR
Halozyme Therapeutics HALO	Option to Purchase Common Stock exercise $106.94, expires Oct 1, 2036, into Common Stock	Directly	1,775	Oct 1, 2026 · Filing · EDGAR
Madrigal Pharmaceuticals MDGL	Common Stock	Directly	3,081	Jun 17, 2026 · Filing · EDGAR
Madrigal Pharmaceuticals MDGL	Stock Option (Right to Buy) exercise $499.86, expires Jun 17, 2036, into Common Stock	Directly	766	Jun 17, 2026 · Filing · EDGAR
Acadia Pharmaceuticals ACAD	Common Stock	Directly	12,148	May 29, 2026 · Filing · EDGAR
Acadia Pharmaceuticals ACAD	Director Stock Options (Right to Buy) exercise $21.66, expires May 28, 2036, into Common Stock	Directly	16,004	May 29, 2026 · Filing · EDGAR
Acadia Pharmaceuticals ACAD	Restricted Stock Units into Common Stock	Directly	9,311	May 29, 2026 · Filing · EDGAR
Bellicum Pharmaceuticals	Common Stock	Directly	109,873	Jan 3, 2023 · Filing · EDGAR
Bellicum Pharmaceuticals	Stock Option (right to buy) exercise $1.11, expires Jun 14, 2032, into Common Stock	Directly	15,000	Jun 15, 2022 · Filing · EDGAR
Chimerix	Stock Option (Right to Buy) exercise $3.37, expires Jun 19, 2029, into Common Stock	Directly	21,000	Jun 20, 2019 · Filing · EDGAR
Incyte	Common Stock	Directly	3,521	Jun 23, 2015 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q4 2025	$671K	$671K
Q1 2025	$5.4M	$5.4M
Q2 2024	$8.2M	$8.7M
Q3 2023	$875K	$850K
Q4 2020	$419K	Not machine-readable
Q3 2020	$1M	Not machine-readable
Q2 2020	$1.3M	Not machine-readable
Q3 2019	$1.1M	Not machine-readable
Q2 2015	$6.5M	Not machine-readable
Q1 2015	$1.8M	Not machine-readable
Q4 2014	$2.2M	Not machine-readable
Q3 2014	$1.6M	Not machine-readable
Q2 2014	$2.6M	Not machine-readable
Q1 2014	$10.5M	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Acadia Pharmaceuticals ACAD · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
Nov 10, 2025	30,000 · ~$671K	Nov 10, 2025	Sold as noticed Sold 30,000 at $22.37 on Nov 10 · $671K Form 4	Filing · EDGAR
Madrigal Pharmaceuticals MDGL · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
Feb 27, 2025	15,470 · ~$5.4M	Feb 27, 2025	Sold as noticed Sold 15,470 in 3 sales, Feb 27 to Feb 27 · $5.4M Form 4	Filing · EDGAR
Madrigal Pharmaceuticals MDGL · Morgan Stanley Smith Barney · 10b5-1 plan adopted Nov 16, 2023 · 1 notice
Apr 1, 2024	32,489 · ~$8.7M	Apr 1, 2024	Sold as noticed Sold 32,489 in 16 sales, Apr 1 to Apr 2 · $8.2M Form 4	Filing · EDGAR
Halozyme Therapeutics HALO · Etrade Financial · No 10b5-1 plan stated · 2 notices
Aug 14, 2023	10,000 · ~$430K	Aug 14, 2023	Sold as noticed Sold 10,000 at $43.74 on Aug 14 · $437K Form 4	Filing · EDGAR
Aug 11, 2023	10,000 · ~$420K	Aug 11, 2023	Sold as noticed Sold 10,000 at $43.71 on Aug 11 · $437K Form 4	Filing · EDGAR
Sales without a matching Form 144 · 25 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 10,363 at $40.41 on Nov 25, 2020 · $419K	Filing · EDGAR
—	—	—	Notice not machine-readable Halozyme Therapeutics (HALO): Sold 34,337 at $29.12 on Aug 13, 2020 · $1M	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 26,250 at $51.13 on May 11, 2020 · $1.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 400 at $38.39 on Sep 9, 2019 · $15K	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 29,600 at $37.79 on Sep 9, 2019 · $1.1M	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 981 at $107.84 on Jun 23, 2015 · $106K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 10,710 at $108.28 on Jun 23, 2015 · $1.2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 981 at $106.00 on May 26, 2015 · $104K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 11,112 at $106.43 on May 26, 2015 · $1.2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 14,718 at $107.67 on Apr 23, 2015 · $1.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 22,223 at $107.67 on Apr 23, 2015 · $2.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 8,334 at $81.77 on Feb 24, 2015 · $681K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 2,778 at $83.44 on Feb 23, 2015 · $232K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 11,109 at $77.68 on Jan 23, 2015 · $863K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 11,113 at $74.43 on Dec 23, 2014 · $827K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 11,111 at $74.08 on Nov 24, 2014 · $823K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 11,111 at $53.49 on Oct 23, 2014 · $594K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 11,111 at $47.65 on Sep 23, 2014 · $529K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 11,111 at $51.96 on Aug 25, 2014 · $577K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 11,111 at $48.54 on Jul 23, 2014 · $539K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 8,334 at $55.92 on Jun 23, 2014 · $466K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 2,777 at $56.38 on Jun 23, 2014 · $157K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 11,111 at $48.48 on May 23, 2014 · $539K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 30,555 at $47.71 on Apr 23, 2014 · $1.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Incyte: Sold 158,331 at $66.49 on Feb 13, 2014 · $10.5M	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Cytokinetics CYTK Director · filings 2025 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 16, 2026	Grant or award from the company	+195	$63.92	$12K	3,585 direct	Filing · EDGAR
Jul 15, 2026	Grant or award from the company	+151	$82.62	$12K	3,390 direct	Filing · EDGAR
May 27, 2026	Grant or award from the company	+2,851			3,239 direct	Filing · EDGAR
May 27, 2026	Grant or award from the company Non-Qualified Stock Option (Right to Buy)	+4,301			4,301 direct	Filing · EDGAR
Apr 15, 2026	Grant or award from the company	+191	$65.37	$12K	388 direct	Filing · EDGAR
Jan 15, 2026	Grant or award from the company	+197	$63.44	$12K	197 direct	Filing · EDGAR
Aug 19, 2025	Grant or award from the company Non-Qualified Stock Option (Right to Buy)	+27,450			27,450 direct	Filing · EDGAR

Halozyme Therapeutics HALO Director · filings 2016 to 2026 · sold $2.3M · $850K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 1, 2026	Grant or award from the company	+1,169			1,169 direct	Filing · EDGAR
Oct 1, 2026	Grant or award from the company Option to Purchase Common Stock	+1,775			1,775 direct	Filing · EDGAR
Aug 14, 2023	Open-market or private sale	−10,000	$43.74	$437K	20,503 direct	Filing · EDGAR
Aug 11, 2023	Open-market or private sale	−10,000	$43.71	$437K	30,503 direct	Filing · EDGAR
May 5, 2023	Grant or award from the company	+8,065			40,503 direct	Filing · EDGAR
May 5, 2023	Grant or award from the company Option to Purchase Common Stock	+11,371			11,371 direct	Filing · EDGAR
May 5, 2022	Grant or award from the company	+6,206			32,438 direct	Filing · EDGAR
May 5, 2021	Grant or award from the company	+5,230			26,232 direct	Filing · EDGAR
Nov 25, 2020	Open-market or private sale	−10,363	$40.41	$419K	21,002 direct	Filing · EDGAR
Aug 13, 2020	Open-market or private sale	−34,337	$29.12	$1M	31,365 direct	Filing · EDGAR
Apr 30, 2020	Grant or award from the company	+8,829			65,702 direct	Filing · EDGAR
May 2, 2019	Grant or award from the company	+12,173			56,873 direct	Filing · EDGAR
May 2, 2018	Grant or award from the company	+10,363			44,700 direct	Filing · EDGAR
May 4, 2017	Grant or award from the company	+14,135			34,337 direct	Filing · EDGAR
May 4, 2016	Grant or award from the company	+20,202			20,202 direct	Filing · EDGAR

Madrigal Pharmaceuticals MDGL Director · filings 2019 to 2026 · sold $13.6M · $14.1M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 17, 2026	Grant or award from the company	+454			3,081 direct	Filing · EDGAR
Jun 17, 2026	Grant or award from the company Stock Option (Right to Buy)	+766			766 direct	Filing · EDGAR
Jun 20, 2025	Grant or award from the company	+715			2,627 direct	Filing · EDGAR
Jun 20, 2025	Grant or award from the company Stock Option (Right to Buy)	+1,290			1,290 direct	Filing · EDGAR
Feb 27, 2025	Option or RSU exercised or converted	+9,470	$65.06	$616K	11,382 direct	Filing · EDGAR
Feb 27, 2025	Option or RSU exercised or converted	+6,000	$111.06	$666K	17,382 direct	Filing · EDGAR
Feb 27, 2025	Open-market or private sale	−398	$346.90	$138K	16,984 direct	Filing · EDGAR
Feb 27, 2025	Open-market or private sale	−14,302	$347.39	$5M	2,682 direct	Filing · EDGAR
Feb 27, 2025	Open-market or private sale	−770	$348.94	$269K	1,912 direct	Filing · EDGAR
Feb 27, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−9,470			0 direct	Filing · EDGAR
Feb 27, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−6,000			0 direct	Filing · EDGAR
Jun 25, 2024	Grant or award from the company	+714			1,912 direct	Filing · EDGAR
Jun 25, 2024	Grant or award from the company Stock Option (Right to Buy)	+1,105			1,105 direct	Filing · EDGAR
Apr 2, 2024	Option or RSU exercised or converted	+10,912	$105.08	$1.1M	12,110 direct	Filing · EDGAR
Apr 2, 2024	Sale under a 10b5-1 plan	−842	$243.26	$205K	11,268 direct	Filing · EDGAR
Apr 2, 2024	Sale under a 10b5-1 plan	−6,279	$244.19	$1.5M	4,989 direct	Filing · EDGAR
Apr 2, 2024	Sale under a 10b5-1 plan	−2,991	$244.89	$732K	1,998 direct	Filing · EDGAR
Apr 2, 2024	Sale under a 10b5-1 plan	−557	$246.30	$137K	1,441 direct	Filing · EDGAR
Apr 2, 2024	Sale under a 10b5-1 plan	−43	$247.03	$11K	1,398 direct	Filing · EDGAR
Apr 2, 2024	Sale under a 10b5-1 plan	−200	$248.45	$50K	1,198 direct	Filing · EDGAR
Apr 2, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,912			0 direct	Filing · EDGAR
Apr 1, 2024	Option or RSU exercised or converted	+20,000	$100.45	$2M	21,198 direct	Filing · EDGAR
Apr 1, 2024	Option or RSU exercised or converted	+1,577	$105.08	$166K	22,775 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−6,809	$255.64	$1.7M	15,966 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−7,401	$256.50	$1.9M	8,565 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−3,604	$257.30	$927K	4,961 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−1,460	$258.28	$377K	3,501 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−200	$259.11	$52K	3,301 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−800	$262.01	$210K	2,501 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−178	$263.31	$47K	2,323 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−351	$264.89	$93K	1,972 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−500	$265.49	$133K	1,472 direct	Filing · EDGAR
Apr 1, 2024	Sale under a 10b5-1 plan	−274	$266.91	$73K	1,198 direct	Filing · EDGAR
Apr 1, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−20,000			0 direct	Filing · EDGAR
Apr 1, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−1,577			10,912 direct	Filing · EDGAR
Jun 15, 2023	Grant or award from the company	+1,198			1,198 direct	Filing · EDGAR
Jun 16, 2022	Grant or award from the company Stock Option (Right to Buy)	+9,470			9,470 direct	Filing · EDGAR
Jun 17, 2021	Grant or award from the company Stock Option (Right to Buy)	+12,489			12,489 direct	Filing · EDGAR
Jun 17, 2020	Grant or award from the company Stock Option (Right to Buy)	+6,000			6,000 direct	Filing · EDGAR
Jun 27, 2019	Grant or award from the company Stock Option (Right to Buy)	+20,000			20,000 direct	Filing · EDGAR

Acadia Pharmaceuticals ACAD Director · filings 2016 to 2026 · sold $3.1M · $671K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
May 29, 2026	Option or RSU exercised or converted	+8,107			12,148 direct	Filing · EDGAR
May 29, 2026	Option or RSU exercised or converted Restricted Stock Units	−8,107			0 direct	Filing · EDGAR
May 29, 2026	Grant or award from the company Director Stock Options (Right to Buy)	+16,004			16,004 direct	Filing · EDGAR
May 29, 2026	Grant or award from the company Restricted Stock Units	+9,311			9,311 direct	Filing · EDGAR
Nov 10, 2025	Open-market or private sale	−30,000	$22.37	$671K	4,041 direct	Filing · EDGAR
May 29, 2025	Option or RSU exercised or converted	+9,387			34,041 direct	Filing · EDGAR
May 29, 2025	Option or RSU exercised or converted Restricted Stock Units	−9,387			0 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Director Stock Options (Right to Buy)	+13,793			13,793 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Restricted Stock Units	+8,107			8,107 direct	Filing · EDGAR
May 29, 2024	Option or RSU exercised or converted	+6,652			24,654 direct	Filing · EDGAR
May 29, 2024	Option or RSU exercised or converted Restricted Stock Units	−6,652			0 direct	Filing · EDGAR
May 29, 2024	Grant or award from the company Director Stock Options (Right to Buy)	+15,959			15,959 direct	Filing · EDGAR
May 29, 2024	Grant or award from the company Restricted Stock Units	+9,387			9,387 direct	Filing · EDGAR
Jun 1, 2023	Option or RSU exercised or converted	+8,552			18,002 direct	Filing · EDGAR
Jun 1, 2023	Option or RSU exercised or converted Restricted Stock Units	−8,552			0 direct	Filing · EDGAR
Jun 1, 2023	Grant or award from the company Director Stock Options (Right to Buy)	+11,045			11,045 direct	Filing · EDGAR
Jun 1, 2023	Grant or award from the company Restricted Stock Units	+6,652			6,652 direct	Filing · EDGAR
Jun 7, 2022	Option or RSU exercised or converted	+6,391			9,450 direct	Filing · EDGAR
Jun 7, 2022	Option or RSU exercised or converted Restricted Stock Units	−6,391			0 direct	Filing · EDGAR
Jun 7, 2022	Grant or award from the company Director Stock Options (Right to Buy)	+14,368			14,368 direct	Filing · EDGAR
Jun 7, 2022	Grant or award from the company Restricted Stock Units	+8,552			8,552 direct	Filing · EDGAR
Jun 22, 2021	Option or RSU exercised or converted	+3,059			3,059 direct	Filing · EDGAR
Jun 22, 2021	Option or RSU exercised or converted Restricted Stock Units	−3,059			0 direct	Filing · EDGAR
Jun 22, 2021	Grant or award from the company Director Stock Options (Right to Buy)	+11,637			11,637 direct	Filing · EDGAR
Jun 22, 2021	Grant or award from the company Restricted Stock Units	+6,391			6,391 direct	Filing · EDGAR
Jun 23, 2020	Grant or award from the company Director Stock Options (Right to Buy)	+5,579			5,579 direct	Filing · EDGAR
Jun 23, 2020	Grant or award from the company Restricted Stock Units	+3,059			3,059 direct	Filing · EDGAR
May 11, 2020	Option or RSU exercised or converted	+11,250	$25.24	$284K	11,250 direct	Filing · EDGAR
May 11, 2020	Option or RSU exercised or converted	+15,000	$27.25	$409K	26,250 direct	Filing · EDGAR
May 11, 2020	Open-market or private sale	−26,250	$51.13	$1.3M	0 direct	Filing · EDGAR
May 11, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−11,250			11,250 direct	Filing · EDGAR
May 11, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−15,000			0 direct	Filing · EDGAR
Sep 9, 2019	Option or RSU exercised or converted	+30,000	$17.52	$526K	30,000 direct	Filing · EDGAR
Sep 9, 2019	Open-market or private sale	−29,600	$37.79	$1.1M	400 direct	Filing · EDGAR
Sep 9, 2019	Open-market or private sale	−400	$38.39	$15K	0 direct	Filing · EDGAR
Sep 9, 2019	Option or RSU exercised or converted Stock Option (Right to Buy)	−30,000			0 direct	Filing · EDGAR
Jun 26, 2019	Grant or award from the company Stock Option (Right to Buy)	−22,500			22,500 direct	Filing · EDGAR
Jun 6, 2018	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR
Jun 6, 2018	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR
Jul 17, 2017	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR
Jun 13, 2017	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR
Jun 10, 2016	Grant or award from the company Stock Option (right to buy)	+12,500			12,500 direct	Filing · EDGAR
Jan 7, 2016	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR

Bellicum Pharmaceuticals Director · filings 2016 to 2023

Date	Transaction	Shares	Held after	Source
Jan 3, 2023	Option or RSU exercised or converted	+60,414	109,873 direct	Filing · EDGAR
Sep 1, 2022	Option or RSU exercised or converted	+35,082	49,459 direct	Filing · EDGAR
Jun 15, 2022	Grant or award from the company Stock Option (right to buy)	+15,000	15,000 direct	Filing · EDGAR
Jan 4, 2022	Option or RSU exercised or converted	+13,568	13,568 direct	Filing · EDGAR
Jan 4, 2022	Option or RSU exercised or converted	+809	14,377 direct	Filing · EDGAR
Jan 4, 2022	Option or RSU exercised or converted Restricted Stock Units	−13,568	0 direct	Filing · EDGAR
Jan 4, 2022	Option or RSU exercised or converted Restricted Stock Units	−809	0 direct	Filing · EDGAR
Jul 1, 2021	Grant or award from the company Restricted Stock Units	+809	809 direct	Filing · EDGAR
Jun 15, 2021	Grant or award from the company Stock Option (right to buy)	+6,500	6,500 direct	Filing · EDGAR
Jan 4, 2021	Grant or award from the company Restricted Stock Units	+13,568	13,568 direct	Filing · EDGAR
Jun 15, 2020	Grant or award from the company Stock Option (right to buy)	+6,500	6,500 direct	Filing · EDGAR
Jun 13, 2019	Grant or award from the company Stock Option (right to buy)	+25,000	25,000 direct	Filing · EDGAR
Jun 14, 2018	Grant or award from the company Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Jun 14, 2017	Grant or award from the company Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Jun 15, 2016	Grant or award from the company Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
May 17, 2016	Grant or award from the company Stock Option (right to buy)	+20,000	20,000 direct	Filing · EDGAR
May 17, 2016	Grant or award from the company Stock Option (right to buy)	+833	833 direct	Filing · EDGAR

Chimerix Director · filings 2014 to 2019

Date	Transaction	Shares	Held after	Source
Jun 20, 2019	Grant or award from the company Stock Option (Right to Buy)	+21,000	21,000 direct	Filing · EDGAR
Jun 20, 2018	Grant or award from the company Stock Option (Right to Buy)	+21,000	21,000 direct	Filing · EDGAR
Jun 28, 2017	Grant or award from the company Stock Option (Right to Buy)	+21,000	21,000 direct	Filing · EDGAR
Jun 24, 2016	Grant or award from the company Stock Option (Right to Buy)	+9,000	9,000 direct	Filing · EDGAR
Jun 22, 2015	Grant or award from the company Stock Option (Right to Buy)	+9,000	9,000 direct	Filing · EDGAR
Jun 20, 2014	Grant or award from the company Stock Option (Right to Buy)	+9,000	9,000 direct	Filing · EDGAR
Jun 20, 2014	Grant or award from the company Stock Option (Right to Buy)	+18,000	18,000 direct	Filing · EDGAR

Incyte EVP, Chief Commercial Officer · filings 2012 to 2015 · sold $25.3M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 23, 2015	Option or RSU exercised or converted	+2,778	$18.32	$51K	6,299 direct	Filing · EDGAR
Jun 23, 2015	Option or RSU exercised or converted	+7,331	$16.62	$122K	13,630 direct	Filing · EDGAR
Jun 23, 2015	Option or RSU exercised or converted	+601	$16.62	$10K	14,231 direct	Filing · EDGAR
Jun 23, 2015	Sale under a 10b5-1 plan	−10,710	$108.28	$1.2M	3,521 direct	Filing · EDGAR
Jun 23, 2015	Option or RSU exercised or converted	+981	$64.55	$63K	4,502 direct	Filing · EDGAR
Jun 23, 2015	Sale under a 10b5-1 plan	−981	$107.84	$106K	3,521 direct	Filing · EDGAR
Jun 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−2,778			16,765 direct	Filing · EDGAR
Jun 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−7,331			30,928 direct	Filing · EDGAR
Jun 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−601			2,407 direct	Filing · EDGAR
Jun 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−981			17,662 direct	Filing · EDGAR
May 26, 2015	Option or RSU exercised or converted	+2,778	$18.32	$51K	6,299 direct	Filing · EDGAR
May 26, 2015	Option or RSU exercised or converted	+7,732	$16.62	$129K	14,031 direct	Filing · EDGAR
May 26, 2015	Option or RSU exercised or converted	+602	$16.62	$10K	14,633 direct	Filing · EDGAR
May 26, 2015	Sale under a 10b5-1 plan	−11,112	$106.43	$1.2M	3,521 direct	Filing · EDGAR
May 26, 2015	Option or RSU exercised or converted	+981	$64.55	$63K	4,502 direct	Filing · EDGAR
May 26, 2015	Sale under a 10b5-1 plan	−981	$106.00	$104K	3,521 direct	Filing · EDGAR
May 26, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−2,778			19,543 direct	Filing · EDGAR
May 26, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−7,732			38,659 direct	Filing · EDGAR
May 26, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−602			3,008 direct	Filing · EDGAR
May 26, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−981			18,643 direct	Filing · EDGAR
Apr 23, 2015	Option or RSU exercised or converted	+1,203	$16.62	$20K	4,724 direct	Filing · EDGAR
Apr 23, 2015	Option or RSU exercised or converted	+15,464	$16.62	$257K	20,188 direct	Filing · EDGAR
Apr 23, 2015	Option or RSU exercised or converted	+5,556	$18.32	$102K	25,744 direct	Filing · EDGAR
Apr 23, 2015	Sale under a 10b5-1 plan	−22,223	$107.67	$2.4M	3,521 direct	Filing · EDGAR
Apr 23, 2015	Option or RSU exercised or converted	+14,718	$64.55	$950K	18,239 direct	Filing · EDGAR
Apr 23, 2015	Sale under a 10b5-1 plan	−14,718	$107.67	$1.6M	3,521 direct	Filing · EDGAR
Apr 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−1,203			3,610 direct	Filing · EDGAR
Apr 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−15,464			46,391 direct	Filing · EDGAR
Apr 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−5,556			22,321 direct	Filing · EDGAR
Apr 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−14,718			19,624 direct	Filing · EDGAR
Feb 24, 2015	Option or RSU exercised or converted	+7,732	$16.62	$129K	11,253 direct	Filing · EDGAR
Feb 24, 2015	Option or RSU exercised or converted	+602	$16.62	$10K	11,855 direct	Filing · EDGAR
Feb 24, 2015	Sale under a 10b5-1 plan	−8,334	$81.77	$681K	3,521 direct	Filing · EDGAR
Feb 24, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−7,732			61,855 direct	Filing · EDGAR
Feb 24, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−602			4,813 direct	Filing · EDGAR
Feb 23, 2015	Option or RSU exercised or converted	+2,778	$18.32	$51K	6,299 direct	Filing · EDGAR
Feb 23, 2015	Sale under a 10b5-1 plan	−2,778	$83.44	$232K	3,521 direct	Filing · EDGAR
Feb 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−2,778			27,877 direct	Filing · EDGAR
Jan 23, 2015	Option or RSU exercised or converted	+7,731	$16.62	$128K	11,252 direct	Filing · EDGAR
Jan 23, 2015	Option or RSU exercised or converted	+601	$16.62	$10K	11,853 direct	Filing · EDGAR
Jan 23, 2015	Option or RSU exercised or converted	+2,777	$18.32	$51K	14,630 direct	Filing · EDGAR
Jan 23, 2015	Sale under a 10b5-1 plan	−11,109	$77.68	$863K	3,521 direct	Filing · EDGAR
Jan 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−7,731			69,587 direct	Filing · EDGAR
Jan 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−601			5,415 direct	Filing · EDGAR
Jan 23, 2015	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−2,777			30,655 direct	Filing · EDGAR
Jan 8, 2015	Grant or award from the company	+3,022			3,521 direct	Filing · EDGAR
Jan 8, 2015	Grant or award from the company Non-Qualified Stock Option (right to buy)	+20,446			20,446 direct	Filing · EDGAR
Jan 8, 2015	Grant or award from the company Incentive Stock Option (right to buy)	+1,099			1,099 direct	Filing · EDGAR
Dec 23, 2014	Option or RSU exercised or converted	+2,778	$18.32	$51K	2,778 direct	Filing · EDGAR
Dec 23, 2014	Option or RSU exercised or converted	+7,833	$16.62	$130K	10,611 direct	Filing · EDGAR
Dec 23, 2014	Option or RSU exercised or converted	+502	$16.62	$8K	11,113 direct	Filing · EDGAR
Dec 23, 2014	Sale under a 10b5-1 plan	−11,113	$74.43	$827K	0 direct	Filing · EDGAR
Dec 23, 2014	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−2,778			33,432 direct	Filing · EDGAR
Dec 23, 2014	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−7,833			77,318 direct	Filing · EDGAR
Dec 23, 2014	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−502			6,016 direct	Filing · EDGAR
Nov 24, 2014	Option or RSU exercised or converted	+2,778	$18.32	$51K	2,778 direct	Filing · EDGAR
Nov 24, 2014	Option or RSU exercised or converted	+7,832	$16.62	$130K	10,610 direct	Filing · EDGAR
Nov 24, 2014	Option or RSU exercised or converted	+501	$16.62	$8K	11,111 direct	Filing · EDGAR
Nov 24, 2014	Sale under a 10b5-1 plan	−11,111	$74.08	$823K	0 direct	Filing · EDGAR
Nov 24, 2014	Option or RSU exercised or converted Non-Qualified Stock Option (right to buy)	−2,778			36,210 direct	Filing · EDGAR

65 earlier transactions are in the filing list below.

All 95 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Oct 20, 2026	Form 4	Cytokinetics CYTK	Filing · EDGAR
Oct 2, 2026	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Oct 2, 2026	Form 3	Halozyme Therapeutics HALO	Filing · EDGAR
Jul 16, 2026	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jun 18, 2026	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Jun 1, 2026	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
May 27, 2026	Form 4	Cytokinetics CYTK	Filing · EDGAR
Apr 15, 2026	Form 4	Cytokinetics CYTK	Filing · EDGAR
Jan 20, 2026	Form 4	Cytokinetics CYTK	Filing · EDGAR
Nov 12, 2025	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Nov 10, 2025	Form 144	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Aug 20, 2025	Form 4	Cytokinetics CYTK	Filing · EDGAR
Aug 20, 2025	Form 3	Cytokinetics CYTK	Filing · EDGAR
Jun 24, 2025	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Jun 2, 2025	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Feb 28, 2025	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Feb 27, 2025	Form 144	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Jun 27, 2024	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
May 31, 2024	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Apr 3, 2024	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Apr 1, 2024	Form 144	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Aug 15, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 14, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 11, 2023	Form 144	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 20, 2023	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Jun 5, 2023	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
May 9, 2023	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 5, 2023	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Sep 2, 2022	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Jun 21, 2022	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Jun 16, 2022	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Jun 9, 2022	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
May 6, 2022	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 6, 2022	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Jul 7, 2021	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Jul 6, 2021	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Jun 24, 2021	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 21, 2021	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
May 6, 2021	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 5, 2021	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Nov 25, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Aug 13, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 25, 2020	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 18, 2020	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Jun 16, 2020	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
May 13, 2020	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
May 1, 2020	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Sep 11, 2019	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jul 1, 2019	Form 4	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Jul 1, 2019	Form 3	Madrigal Pharmaceuticals MDGL	Filing · EDGAR
Jun 28, 2019	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 24, 2019	Form 4	Chimerix	Filing · EDGAR
Jun 14, 2019	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
May 3, 2019	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 21, 2018	Form 4	Chimerix	Filing · EDGAR
Jun 18, 2018	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Jun 8, 2018	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
May 2, 2018	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jul 19, 2017	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 29, 2017	Form 4	Chimerix	Filing · EDGAR
Jun 15, 2017	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Jun 14, 2017	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
May 5, 2017	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Jun 28, 2016	Form 4	Chimerix	Filing · EDGAR
Jun 17, 2016	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
Jun 10, 2016	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
May 19, 2016	Form 4	Bellicum Pharmaceuticals	Filing · EDGAR
May 19, 2016	Form 3	Bellicum Pharmaceuticals	Filing · EDGAR
May 6, 2016	Form 4	Halozyme Therapeutics HALO	Filing · EDGAR
Mar 8, 2016	Form 3	Halozyme Therapeutics HALO	Filing · EDGAR
Jan 11, 2016	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jan 11, 2016	Form 3	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 25, 2015	Form 4	Incyte	Filing · EDGAR
Jun 24, 2015	Form 4	Chimerix	Filing · EDGAR
May 28, 2015	Form 4	Incyte	Filing · EDGAR
Apr 24, 2015	Form 4	Incyte	Filing · EDGAR
Feb 25, 2015	Form 4	Incyte	Filing · EDGAR
Jan 26, 2015	Form 4	Incyte	Filing · EDGAR
Jan 9, 2015	Form 4	Incyte	Filing · EDGAR
Dec 29, 2014	Form 4	Incyte	Filing · EDGAR
Nov 26, 2014	Form 4	Incyte	Filing · EDGAR
Oct 24, 2014	Form 4	Incyte	Filing · EDGAR
Sep 25, 2014	Form 4	Incyte	Filing · EDGAR
Aug 27, 2014	Form 4	Incyte	Filing · EDGAR
Jul 25, 2014	Form 4	Incyte	Filing · EDGAR
Jun 25, 2014	Form 4	Incyte	Filing · EDGAR
Jun 23, 2014	Form 4	Chimerix	Filing · EDGAR
Jun 23, 2014	Form 3	Chimerix	Filing · EDGAR
May 28, 2014	Form 4	Incyte	Filing · EDGAR
Apr 25, 2014	Form 4	Incyte	Filing · EDGAR
Feb 18, 2014	Form 4	Incyte	Filing · EDGAR
Jan 23, 2014	Form 4	Incyte	Filing · EDGAR
Feb 12, 2013	Form 4	Incyte	Filing · EDGAR
Oct 23, 2012	Form 4	Incyte	Filing · EDGAR
Oct 23, 2012	Form 3	Incyte	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 8, 2026, 5:19 AM ET. The filing on SEC.gov is the record.